Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHVNASDAQ:CRISNASDAQ:DOMHNASDAQ:FBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$2.07-5.0%$3.01$1.84▼$5.31$75.61M1.51266,512 shs1.69 million shsCRISCuris$1.74-3.9%$2.19$1.02▼$8.29$18.94M3.680,752 shs243,319 shsDOMHDominari$5.10-3.2%$5.24$0.83▼$13.58$77.17M0.61272,657 shs181,933 shsFBIOFortress Biotech$1.91+1.6%$1.82$1.33▼$2.89$55.59M1.75413,143 shs631,273 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%-1.35%-42.56%-0.90%-51.54%CRISCuris0.00%-15.21%-22.36%+58.62%-71.16%DOMHDominari0.00%-5.05%-2.41%+48.03%+180.32%FBIOFortress Biotech0.00%+4.89%-4.55%+29.86%+6.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences1.1528 of 5 stars3.80.00.00.00.60.00.6CRISCuris2.879 of 5 stars3.55.00.00.02.30.00.6DOMHDominari0.3539 of 5 stars0.02.00.00.00.02.50.6FBIOFortress Biotech2.1261 of 5 stars3.51.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.33592.43% UpsideCRISCuris 3.00Buy$17.00877.01% UpsideDOMHDominari 0.00N/AN/AN/AFBIOFortress Biotech 3.00Buy$21.00999.48% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, DOMH, ACHV, and FBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/ACRISCuris$10.91M1.67N/AN/A($0.71) per share-2.45DOMHDominari$18.15M4.11N/AN/A$5.71 per share0.89FBIOFortress Biotech$57.67M0.98N/AN/A($0.06) per share-31.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)CRISCuris-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%7/30/2025 (Estimated)DOMHDominari-$14.70M-$4.50N/A∞N/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)Latest CRIS, DOMH, ACHV, and FBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million4/15/2025Q4 2024DOMHDominariN/A$0.20N/A$0.20N/A$6.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.853.513.51CRISCurisN/A1.231.23DOMHDominariN/A5.745.74FBIOFortress Biotech1.741.721.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%CRISCuris29.97%DOMHDominari42.48%FBIOFortress Biotech96.51%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%CRISCuris5.70%DOMHDominari32.98%FBIOFortress Biotech27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2034.69 million33.64 millionOptionableCRISCuris6010.46 million9.87 millionNo DataDOMHDominari414.64 million9.81 millionNot OptionableFBIOFortress Biotech17029.57 million21.32 millionOptionableCRIS, DOMH, ACHV, and FBIO HeadlinesRecent News About These CompaniesFBIO Fortress Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comJourney Medical to Join Russell 2000® and Russell 3000® IndexesJune 24, 2025 | globenewswire.comFortress Biotech (NASDAQ:FBIO) Stock Passes Above 200-Day Moving Average - Here's WhyJune 21, 2025 | marketbeat.comJourney Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology ConferenceJune 20, 2025 | globenewswire.comDespite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain StockJune 19, 2025 | zacks.comJourney Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TVJune 9, 2025 | globenewswire.comFortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced MomentumJune 3, 2025 | zacks.comFortress Biotech Announces Closing of Sale of Subsidiary Checkpoint TherapeuticsMay 30, 2025 | globenewswire.comFortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 16, 2025 | finanznachrichten.deNew Strong Sell Stocks for May 16thMay 16, 2025 | zacks.comFortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 15, 2025 | globenewswire.comJourney Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 14, 2025 | globenewswire.comCheckpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesMay 13, 2025 | globenewswire.comJourney Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025May 7, 2025 | globenewswire.comFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7, 2025 | globenewswire.comWhy Fortress Biotech, Inc.’s (FBIO) Stock Is Down 6.18%May 7, 2025 | aaii.comAThis Fortress Biotech Insider Increased Their Holding By 26% Last YearApril 9, 2025 | finance.yahoo.comJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerApril 1, 2025 | globenewswire.comFortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2025 | zacks.comFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsMarch 31, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseThe Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingBy Leo Miller | July 2, 2025View The Ultimate Trump Bump: These Gov't Backed Stocks Are ExplodingCRIS, DOMH, ACHV, and FBIO Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$2.07 -0.11 (-5.05%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.05 (+2.61%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Curis NASDAQ:CRIS$1.74 -0.07 (-3.87%) Closing price 04:00 PM EasternExtended Trading$1.72 -0.02 (-1.15%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Dominari NASDAQ:DOMH$5.10 -0.17 (-3.23%) As of 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Fortress Biotech NASDAQ:FBIO$1.91 +0.03 (+1.60%) Closing price 04:00 PM EasternExtended Trading$1.99 +0.08 (+4.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
